A Phase IIb/III Randomized Multicenter Active Control to evaluate Efficacy and Safety of topical application of recombinant Lysostaphin (150µg/g) gel formulation in subjects with uncomplicated Staphylococcus aureus and Methicillin resistant Staphylococcus aureus skin and skin structure infections.

Trial Profile

A Phase IIb/III Randomized Multicenter Active Control to evaluate Efficacy and Safety of topical application of recombinant Lysostaphin (150µg/g) gel formulation in subjects with uncomplicated Staphylococcus aureus and Methicillin resistant Staphylococcus aureus skin and skin structure infections.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Lysostaphin (Primary) ; Mupirocin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Bharat Biotech
  • Most Recent Events

    • 13 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top